The effect of lymphadenectomy and radiotherapy on recurrence and survival in endometrial carcinoma. Experience in a population reference centre

Aim

To evaluate the effect of lymphadenectomy and/or radiotherapy on recurrence and survival patterns in endometrial carcinoma (EC) in a radiotherapy reference centre population.

Material and Methods

A retrospective population-based review was conducted on 261 patients with stages I–III EC. Univariate and multivariate analyses were carried out. Both recurrence and survival were analysed according to patient age, FIGO stage, tumour size, myometrial invasion, tumour grade, lymphadenectomy, external beam irradiation (EBI), and brachytherapy (BT).

Results

Median age: 64.8 years. Median follow-up: 151 months. The following treatments were administered: surgery, 97.32%; lymph-node dissection, 54.4%; radiotherapy, 162 patients (62%) (EBI and BT: 64.1%, BT alone: 30.2%, EBI alone: 5.6%).Twenty-six patients (9.96%) suffered loco-regional recurrence, whilst 27 (10.34%) suffered distant failure. The 5-year overall survival (OS) for all stages was 80.1%. The 5-year disease free survival (DFS) was 92.1% for all patients. The 10-year DFS was 89.9%.The independent significant prognostic factors for a good outcome identified through the multivariate analysis were: age <75 years (p = 0.001); tumour size ≤2 cm (p = 0.003); myometrial invasion ≤50% (p = 0.011); lymphadenectomy (p = 0.02); EBI (p = 0.001); and BT (p = 0.031).Toxicity occurred in 114 of the 162 patients who received radiotherapy (70.5%). The toxicity was mainly acute, and late in only 28.3% (n = 45) of cases. The majority experienced G1-2 toxicity, and only 3% of patients experienced G3 late toxicity (5/162).

Conclusions

Our results suggest that age <75 years, tumour size ≤2 cm, myometrial invasion ≤50%, lymphadenectomy, EBI, and BT, are predictors of a good outcome in EC.     

孔腔镜肺叶切除及淋巴结清扫术围手术期应用不同剂量氨溴索对肺癌患者的作用研究

摘要 目的：探讨围手术期应用不同剂量氨溴索对行单孔腔镜肺叶切除及淋巴结清扫术的肺癌患者的作用。方法：选取本院2017年1月至2018年12月期间收治的124例肺癌患者作为受试者,结合患者意愿按随机数字表法将受试者分为小剂量组（n=41）、中剂量组（n=41）和大剂量组（n=42）,术前1d开始给予氨溴索静脉滴注,术后持续7d,比较各组患者临床症状、治疗前后的肺功能、炎症因子、T细胞亚群水平变化及不良反应发生率。结果：大剂量组咳痰容易人数所占比例高于小剂量组,痰液稀薄人数所占比例高于中剂量组及小剂量组（P<0.05）。治疗后大剂量组第一秒用力呼吸容积（FEV¹）、FEV¹/用力肺活量（FVC）高于中剂量组、小剂量组（P<0.05）。治疗后各组炎症因子水平均高于治疗前,且随着剂量的升高,C反应蛋白（CRP）、白介素-6（IL-6）、白介素-8（IL-8）水平呈降低的趋势（P<0.05）。随着剂量的升高,治疗后的 CD3⁺、CD4⁺、CD4⁺/CD8⁺均呈升高趋势,CD8⁺呈降低趋势（P<0.05）。各组不良反应发生率比较无统计学差异（P>0.05）。结论：肺癌患者行单孔腔镜肺叶切除及淋巴结清扫术围手术期应用120mg氨溴索,可加快患者术后恢复,保护患者肺功能,抑制炎症反应,改善患者的免疫功能和临床症状。     

不同切口下乳腺癌根治术的临床疗效对比分析

目的:探讨不同切口下乳腺癌根治术的临床效果。方法:将140例乳腺癌患者根据治疗方法的不同分为对照组60例和治疗组80例,两组都行乳腺癌改良根治术,对照组采用Halsted-Meyer纵切口,治疗组采用Stewart横切口。比较两组手术并发症的发生情况、术后局部复发与远处转移的情况以及生存质量的改变情况。结果:所有患者都顺利完成手术,与对照组相比,治疗组术后皮瓣下积液、皮瓣坏死、上肢淋巴水肿的并发症发生率均明显降低(P0.05),术后躯体、心理、社会支持、精神评分均明显升高(P0.05),术后6个月的局部复发率与远处转移率均明显降低(P0.05)。结论:横切口下实施乳腺癌改良根治术能减少术后并发症,提高患者的术后生存质量,改善患者的远期预后。     

不同术式治疗早期卵巢颗粒细胞瘤的预后分析

目的：探讨不同术式对早期卵巢颗粒细胞瘤初治患者预后的影响。方法：收集2000年1月～2008年12月我院收治的39例早期卵巢颗粒细胞瘤患者的临床资料,分析不同术式对肿瘤复发和预后的影响。结果：39例患者中,行全面分期手术者20例,其中7例仅予盆腔及腹主动脉旁淋巴结活检而未予淋巴结清扫,所有淋巴结术后病理皆提示无淋巴转移;19例行非全面分期手术。随访期间,全面分期手术组皆无复发,而非全面分期手术组4例复发,两组患者术后3年的复发率分别为0和21%,具有统计学差异（P〈0.05）;非全面分期手术组有1例患者于术后29月死亡,死亡年龄为72岁,全面分期手术组无死亡病例,两组患者的死亡率不具有统计学差异（P〉0.05）。结论：原发性卵巢颗粒细胞瘤罕有淋巴结转移,早期卵巢颗粒细胞瘤行全面分期手术对于明确肿瘤分期、治疗及预后有重要意义,而全面分期手术中行盆腔及腹主动脉旁淋巴结清扫对于肿瘤的复发意义有限,初治患者全面分期手术时可不予淋巴清扫。     

Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer

Recent important studies that include long-term follow-up have shown that BRAF and RAS mutations can have negative implications for disease recurrence and survival. BRAF positivity has been shown to be associated with decreased survival and is an independent predictor of poor prognosis. Reliable pre-operative identification of high-risk papillary thyroid cancer (PTC) patients may productively guide initial surgical management since reoperative neck surgery is associated with increased morbidity. However, it is probably too early to conclude that at present it is possible to tailor surgical therapy patient by patient only on the basis of their mutational status. Other important parameters, not including molecular testing, represented by some specific morphological aspects, still play an important role, probably still more significant than molecular diagnostics, such as neck ultrasonography. Pre-operative knowledge of BRAF-positive PTC could alter the initial surgical treatment for at least 20% of patients and can potentially prevent the increased morbidity associated with reoperative neck exploration. However, additional multi-institutional and randomized studies will be needed to further define the role of the pre-operative identification of BRAF positivity to guide not only the initial extent of total thyroidectomy (TT) but also the need for and extent of lymphadenectomy.